Navigation Links
Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Date:8/18/2008

3 in the second quarter of 2008, compared to $109,153 in the second quarter of 2007. General and administrative expenses were $542,043, down from $988,233 in the second quarter of 2007.

Operating income was $2.8 million in the second quarter of 2008 compared to $3.6 million in the second quarter of 2007.

Net income for the second quarter of 2008 was $2.2 million, or $0.05 per diluted share, compared to $3.0 million, or $0.07 per fully diluted share, in the second quarter of 2007.

Adjusting net income for non-cash financing costs associated with its convertible notes and convertible preferred stock, adjusted net income was $2.5 million, or $0.06 per fully diluted share, in the second quarter of 2008, compared to adjusted net income of $3.4 million, or $0.08 per fully diluted share, in the second quarter of 2007.

Six Month Financial Results

Revenues for the first six months of 2008 were $31.1 million, up 47.4% from revenues of $21.1 million in the first six months of 2007. Gross profit was $13.6 million, up 67.8% from gross profit of $8.1 million for the six months of 2007. Gross margin was 43.8%, compared to 38.5% for the first six months of 2007. Operating income was $4.3 million, compared to $4.8 million for the first six months of fiscal 2007.

Net income was $3.2 million, or $0.07 per fully diluted share, compared to $3.9 million, or $0.09 per fully diluted share, for the first six months of fiscal 2007.

Adjusting net income for non-cash financing costs associated with its convertible notes and convertible preferred stock, adjusted net income was $3.9 million, or $0.08 per fully diluted share, for the first six months of 2008, compared to adjusted net income of $4.4 million, or $0.10 per fully diluted share, for the first six months of 2007.

Financial Condition

As of June 30, 2008, Lotus had $3.4 million in cash and equivalents, and $27.0 million of working capital. Total assets were $49.0 million comp
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Calif. , July 29, 2014 Human ... and therapeutic company focused on extending the healthy, high ... Franz Och , Ph.D., an expert in machine ... Scientist. Och comes to HLI from Google where he ... Translate. He will report directly to HLI Co-Founder and ...
(Date:7/29/2014)... (July 29, 2014) Tough, ultralight foam of ... shape through a chemical process invented at Rice University. ... looks like a nanoscale building, with floors and walls ... pair of two-dimensional materials: floors and walls of graphene ... nitride platelets. , The researchers say the foam ...
(Date:7/29/2014)... CITY, Md. , July 29, 2014 /PRNewswire/ ... announced a new and updated program for the ... 10 – 12, 2014 in Amelia Island ... CROs, sites and investigators remains unchanged, however, the ... purposeful exchange and networking opportunity among all stakeholders ...
(Date:7/29/2014)... 2014 Second generation biofuels are a viable ... fuels. However, as natural gas is very cheap, this is ... not as valuable as they could be in comparison to ... projects, has made it difficult for renewable energy developers to ... the ground. For these reasons, certain companies have shifted their ...
Breaking Biology Technology:Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3Tough foam from tiny sheets 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2
... 5 Celator Pharmaceuticals today,announced that Andrew Janoff, ... the company,s business operations and clinical development,programs at ... Investor Conference on Tuesday, February 12, 2008 at ... About Celator, Celator Pharmaceuticals, Inc., is ...
... RICHMOND, Va., Feb. 5 Insmed Inc. (Nasdaq:,INSM) CEO ... House FY09 Budget and Food and Drug Administration statements ... is very pleased to see that the White House ... to,deliver safe and more affordable medicines to Americans., ...
... BioSeek, Inc. today,announced that Roy A. Whitfield has ... directors. Mr. Whitfield had joined BioSeek,s board of,directors ... Company since November,2005., "Roy,s management experience and ... extraordinarily valuable to BioSeek thus,far. We look forward ...
Cached Biology Technology:Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics 2BioSeek Elects Roy Whitfield Executive Chairman of Board of Directors 2
(Date:7/28/2014)... additional coral communities showing signs of damage from the Deepwater ... spill in the Gulf of Mexico. The discovery was made ... at Penn State University. A paper describing this work and ... of Mexico will be published during the last week of ... Proceedings of the National Academy of Sciences . , ...
(Date:7/28/2014)... Essigmann and colleagues from the University of Washington had a ... could induce the virus to mutate uncontrollably, they could force ... that our immune system uses against many viruses. , ... mutate at an enhanced rate, as expected. But it did ... trial reported in 2011. In a new study, however, Essigmann ...
(Date:7/28/2014)... Alzheimer,s disease and other forms of dementia, but the ... , University of Washington bioengineers have a designed a ... the body,s normal proteins into a state that,s linked ... Type 2 diabetes and Lou Gehrig,s disease. The synthetic ... normal state into an abnormally folded form by targeting ...
Breaking Biology News(10 mins):Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... State University scientists and practitioners is riding herd on ... billion cattle industry: Bovine Respiratory Disease. BRD is ... United States, accounting for approximately 75 percent of feedlot ... feedlot deaths. BRD causes between $800 million to $900 ...
... (March 5, 2010) Research presented by P&G Beauty ... the American Academy of Dermatology (Miami Beach, FL, March ... insights into how ingredient formulations, care regimens and gene ... discussing a wide range of topics, including lipid metabolism ...
... (March 4, 2010) -- In a leap toward making stem ... Institute at Weill Cornell Medical College have discovered that endothelial ... produce growth factors that can grow copious amounts of adult ... Until now, adult stem cell cultures would die within four ...
Cached Biology News:Bovine respiratory disease 2P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 2P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 3P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 4Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 2Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 3Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 4Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 5Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 6
... is ideal for the ... (1D electrophoresis, 2D electrophoresis, ... Pharmacokinetics & Toxicology (whole ... chromatography); Physical and Material ...
This kit is designed to select cells labeled with fluorescein isothiocyanate- (FITC-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Fujifilm BAS-1800II provides the ideal configuration for a low-cost imager that requires only a small amount of space in the laboratory. The small imager for accurate high-throughput screening...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
Biology Products: